Xenetic Biosciences (NASDAQ:XBIO) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Xenetic Biosciences (NASDAQ:XBIO) posted its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.14), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 47.21%. The company had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million.

Xenetic Biosciences Price Performance

XBIO traded up $0.01 on Thursday, reaching $3.66. 15,791 shares of the company’s stock were exchanged, compared to its average volume of 11,249. The stock’s fifty day moving average price is $3.89 and its 200-day moving average price is $3.93. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20. The stock has a market cap of $5.64 million, a PE ratio of -1.38 and a beta of 2.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a research note on Tuesday, August 20th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.